APA (7th ed.) Citation

KP, R., C, B., GAAM, S., JWA, B., SW, N., GM, C., . . . IHJT, d. H. (2019). Perioperative systemic therapy and cytoreductive surgery with HIPEC versus upfront cytoreductive surgery with HIPEC alone for isolated resectable colorectal peritoneal metastases: Protocol of a multicentre, open-label, parallel-group, phase II-III, randomised, superiority study (CAIRO6). BMC cancer, 19(1), 390. https://doi.org/10.1186/s12885-019-5545-0

Chicago Style (17th ed.) Citation

KP, Rovers, et al. "Perioperative Systemic Therapy and Cytoreductive Surgery with HIPEC Versus Upfront Cytoreductive Surgery with HIPEC Alone for Isolated Resectable Colorectal Peritoneal Metastases: Protocol of a Multicentre, Open-label, Parallel-group, Phase II-III, Randomised, Superiority Study (CAIRO6)." BMC Cancer 19, no. 1 (2019): 390. https://doi.org/10.1186/s12885-019-5545-0.

MLA (9th ed.) Citation

KP, Rovers, et al. "Perioperative Systemic Therapy and Cytoreductive Surgery with HIPEC Versus Upfront Cytoreductive Surgery with HIPEC Alone for Isolated Resectable Colorectal Peritoneal Metastases: Protocol of a Multicentre, Open-label, Parallel-group, Phase II-III, Randomised, Superiority Study (CAIRO6)." BMC Cancer, vol. 19, no. 1, 2019, p. 390, https://doi.org/10.1186/s12885-019-5545-0.